贝伐单抗作为抗 VEGFR 通路的药物应用于肺癌临床治疗价值分析被引量：5

Clinical application value of bevacizumab as anti-VEGFR pathway drug in lung cancer

导出

摘要目的：探讨贝伐单抗联合化疗应用于肺癌临床治疗的价值。方法选取2015年1月至2016年1月在我院治疗的晚期非鳞癌非小细胞肺癌患者60例,将患者分为观察组（n =30）和对照组（n =30）。观察组接受贝伐单抗联合培美曲塞加铂类方案化疗,对照组接受培美曲塞加铂类方案,观察2组治疗疗效。结果观察组肿瘤客观缓解率为53.33%,明显高于对照组（26.67%）,差异有统计学意义（χ2=4.444,P 〈0.05）；观察组和对照组临床获益率分别为80.00%和63.33%,差异无统计学意义（χ2=2.052,P 〉0.05）；观察组中位生存期为13个月（95% CI ：9.99-14.51）,对照组中位生存期为10个月（95% CI ：9.05-11.95）,2组中位生存期比较差异有统计学意义（χ2=5.255,P 〈0.05）；观察组出现高血压症状的比例为26.67%,明显高于对照组（3.33%）,差异有统计学意义（χ2=6.405,P 〈0.05）,其余不良反应比较差异均无统计学意义（P 值均〉0.05）。结论贝伐单抗联合化疗治疗非鳞癌非小细胞肺癌有较好的临床疗效,可延长患者生存时间。 Objective To investigate value of bevacizumab combined with chemotherapy in the treatment of lung cancer.Methods 60 patients with advanced non squamous cell non-small cell lung cancer were selected,who were treated in our hospital from January 201 5 to January 201 6.The patients were divided into observation group（n =30）and control group（n =30）.The observation group received bevacizumab combined with pemetrexed plus platinum chemotherapy,the control group received pemetrexed plus platinum chemotherapy.The curative effect of the two groups were observed.Results The tumor objective remission rate of observation group was 53.33%,which was significantly higher than that of control group（26.67%,χ2=4.444,P 〈0.05）.The clinical benefit rates of observation group and control group were 80.00% and 63.33%,the difference was not statistically significant（χ2=2.052,P 〉0.05）.The median survival time of observation group was 13 months （95% CI ：9.99-14.5 1）,median survival time of control group was 10 months （95% CI ：9.05-1 1.95）,the difference was statistically significant（χ2 =5.255,P 〈0.05）.The proportion of hypertension symptoms in the observation group was 26.67%,significantly higher than that in the control group （3.33%,χ2 =6.405,P 〈0.05）.There was no statistical significance in the other adverse reactions between the two groups （all P 〉 0.05）. Conclusions Bevacizumab combined chemotherapy has better clinical efficacy and prolong survival time for non squamous cell non-small cell lung cancer.

作者陈瑞琳张程程张永庆吴桦杨淑梅

机构地区陕西省人民医院呼吸内科

出处《国际呼吸杂志》 2016年第18期1372-1375,共4页 International Journal of Respiration

关键词贝伐单抗非鳞癌非小细胞肺癌联合化疗 Bevacizumab Non squamous cell non-small cell lung cancer carcinoma Combined chemotherapy

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献15

1Ebisawa Y, Chisato N, Okayama T, et al. Long-term survivalof a patient with advanced colon cancer and para-aortic lymphnode metastases treated with re-administration of high-dosemolecular targeted agent bevacizumab [J] . Gan To KagakuRyoho,2013,40(10):1401-1404.
2杨晓利,王峰,何炜,樊青霞.贝伐单抗联合培美曲塞加顺铂一线治疗Ⅳ期非小细胞肺癌的临床观察[J].西安交通大学学报（医学版）,2013,34(4):554-556. 被引量：47
3韩娜,张孟贤,于世英,程熠.贝伐单抗联合顺铂/培美曲塞治疗非鳞癌性非小细胞肺癌恶性胸腔积液的临床研究[J].华中科技大学学报（医学版）,2013,42(5):588-591. 被引量：53
4Tokarski S, Rutkowski M, Godala M, et al. The impact ofascorbic acid on the concentrations of antioxidative vitaminsin the plasma of patients with non-small cell lung cancerundergoing first-line chemotherapy [J] . Pol Merkur Lekarski,2013,35(27):136-140.
5刘晓晴,李锋.晚期非鳞非小细胞肺癌一线诱导化疗后贝伐单抗联合培美曲塞维持治疗的疗效和安全性[J].循证医学,2014,14(1):33-36. 被引量：5
6Chan BA, Coward JI. Chemotherapy advances in small-celllung cancer [J] . J Thorac Dis, 2013, 5 Suppl 5: S565-578.DOI: 10. 3978/j. issn. 2072-1439. 2013. 07. 43.
7Zaric B, Stojsic V,Tepavac A, et al. Adjuvant chemotherapyand radiotherapy in the treatment of non-small cell lungcancer (NSCLC) [J] . J Thorac Dis, 2013, 5 ( Suppl 4) : S371-377. DOI: 10. 3978/j. issn. 2072-1439. 2013. 05.16.
8Bergot E, Levallet G,Campbell K, et al. Predictive biomarkersin patients with resected non-small cell lung cancer treatedwith perioperative chemotherapy [J] . Eur Respir Rev, 2013,22(130) :565-576. DOI: 10.1183/09059180.00007113.
9Kim H,Yun T, Lee YJ, et al. Post-progression survival inpatients with non-small cell lung cancer with clinicallyacquired resistance to gefitinib[J] . J Korean Med Sci, 2013, 28?11) :1595-1602. D01:10. 3346/jkms. 2013. 28.11. 1595.
10Fan Y, Huang Z, Mao W. Bevacizumab treatment foradvanced non-small cell lung cancer: A case report [J] . OncolLett, 2013,6(6) :1779-1783. DOI: 10. 3892/ol. 2013.1603.

二级参考文献31

1周立霞,哈敏文.贝伐单抗联合培美曲塞加卡铂二线治疗晚期非小细胞肺癌的临床观察[J].中国药房,2011,22(6):529-531. 被引量：11
2D'ADDARIO G, FRUH M, RECK M, et al. Metastatic nonsmall-cell lung cancer, ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J]. Ann Oneal, 2010, 21 (S): 116-119.
3BALDWIN CM, PERRY CM. Pemetrexed , a review of its use in the management of advanced non-squamous non-small cell lung cancer [J]. Drugs. 2009, 69(16): 2279-2302.
4JARDIM DLF. GAALIATO DDM. RIBEIRO KB. et al. Bevacizumab as first-line therapy in advanced non-small-cell lung cancer: A Brazilian center experience [J]. Drugs RD. 2012, 12(14) :207-216.
5CRIN6 L. DANSIN E. GARRIDO P. et al. Safety and efficacy of first-line bevacizurnab-based therapy in advanced nonsquamous non-small-cell lung cancer (SAiL, MOI9390): a phase 4 study [J]. Lancet Oncol , 2010, 11(8) :733-740.
6SCAGLIOTI G, PARIKH p, VON PAWEL J, et al. Phase 1lI study comparing cisplatin plus gemcitabion with cisplatin plus pernetrexed in chemotherapy: native patients with advancedstage non-small cell lung cancer [J]. J Clin Oncol , 2008, 26 (21) ,3543-3551.
7WAQSTAFF AJ, KEAM SJ, MCCORMACK PL. Bevacizumab plus platinum-based chemotherapy: in advanced non-small cell lung cancer [J]. Bio Drugs, 2009, 23(3):187-196.
8TENG LS, JIN KT, HE KF, et al. Advances in combination of antiangiogenic agents targeting VEGF-binding and conventional chemotherapy and radiation for cancer treatment [J]. J Chin Med Assoc , 2010, 73 (6) ,281-288.
9VAZIRI SA, KIM J, GANAPATHI MK. et al. Vascular endothelial growth factor polymorphisms. role in response and toxicity of tyrosine kinase inhibitors [J]. CUrT Oneol Rep, 2010, 12(2),102-108.
10CHOWDURY MW, SCARAMUZZI RJ, WHEELER-JONES Cp, et al. The expression of angiogenic growth factors and their receptors in ovarian follicles throughout the estrous cycle in the ewe [J]. Theriogenology , 2010,73(7) :856-872.